Donepezil-associated survival benefits among Alzheimer's disease patients are retained but not enhanced during COVID-19 infections.
Elizabeth A EdmistonTaissa A BejBrigid M WilsonRobin L P JumpJoy A PhillipsPublished in: Therapeutic advances in infectious disease (2023)
The known survival benefits of donepezil were retained but not found to be specific to COVID-19 among people with Alzheimer's disease.